Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. - Wikidata - wikimedia - TriplyDB

Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care.

Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care.

http://www.wikidata.org/entity/Q36492436

about

Human Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining Conditions Management of HIV/AIDS in older patients-drug/drug interactions and adherence to antiretroviral therapy Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus Population ancestry and genetic risk for diabetes and kidney, cardiovascular, and bone disease: modifiable environmental factors may produce the cures Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012 Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment Application of marginal structural models in pharmacoepidemiologic studies: a systematic review.Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure Antiretroviral therapy: current drugs Gene-gene and gene-environment interactions in apolipoprotein L1 gene-associated nephropathy.Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.Co-morbidity, ageing and predicted mortality in antiretroviral treated Australian men: a quantitative analysis Cystatin C-based renal function changes after antiretroviral initiation: a substudy of a randomized trial.Protease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review.Relationships between Serum Levels of Atazanavir and Renal Toxicity or Lithiasis.Redoxal, an inhibitor of de novo pyrimidine biosynthesis, augments APOBEC3G antiviral activity against human immunodeficiency virus type 1.Renal Function in Chinese HIV-Positive Individuals following Initiation of Antiretroviral Therapy.Proteinuria is common among HIV patients: what are we missing?Markers of renal disease and function are associated with systemic inflammation in HIV infection.Examination of Potential Modifiers of the Association of APOL1 Alleles with CKD Progression.Thirty-day hospital readmissions for adults with and without HIV infection.Tenofovir exposure alters associations of serum bicarbonate with chronic kidney disease risk in HIV-infected veterans Frequent injection cocaine use increases the risk of renal impairment among hepatitis C and HIV coinfected patients.Kidney disease in children and adolescents with perinatal HIV-1 infection.Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy.Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals.Thirty-day hospital readmission rate among adults living with HIV Incidence of stage 3 chronic kidney disease and progression on tenofovir-based regimens HIV infection with viro-immunological dissociation in a patient with polycystic kidney disease: Candidate for transplantation?Serious Non-AIDS events: Immunopathogenesis and interventional strategies.Plasma apolipoprotein L1 levels do not correlate with CKD.Urine liver-type fatty acid-binding protein and kidney injury molecule-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir.Effect of Tenofovir Disoproxil Fumarate on Incidence of Chronic Kidney Disease and Rate of Estimated Glomerular Filtration Rate Decrement in HIV-1-Infected Treatment-Naïve Asian Patients: Results from 12-Year Observational Cohort.Organ Transplantation and HIV Progress or Success? A Review of Current Status.Risk of coronary heart disease in patients with HIV infection.APOL1 nephropathy: from gene to mechanisms of kidney injury.Monitoring of kidney function in HIV-positive patients.Hepatitis C virus increases the risk of kidney disease among HIV-positive patients: Systematic review and meta-analysis.Chronic kidney disease in Australian HIV-infected patients: analysis of the Australian HIV Observational Database.

P2860

Q26740117-C96713E8-B11F-451A-B109-563C20EC2ABA Q26775832-662F1117-5333-4CC3-B5C8-E72EFBDEE57F Q26851535-AEAF8775-7663-4FF6-A718-29BEE113150D Q28391758-FF5B49F0-9946-4CD8-BF82-768753628169 Q28533843-984DE53C-3ACD-4E3D-B8D5-2905EBA6824C Q28554081-33CB2ECA-D257-4F47-A166-179E41035C7C Q33707284-7A7B251F-CB59-461F-A4C8-F0D4A2052D46 Q33880241-41779183-E95D-47D8-9E35-FD91B0641957 Q34085926-28B791FF-AF21-494E-B382-DC2ABB66FCFA Q34455119-39990597-9F64-4C6E-9647-C7B397A6E7FD Q34736194-B2593628-D868-457E-8849-563D05ACF8FA Q35036409-C6FD4187-6D4C-41AB-8FF7-4BECFA63B2B8 Q35071954-9ADC2EB3-D84C-40E2-BC3D-AABB59376CC3 Q35186842-130A61CE-E414-468E-B4C9-E777A0037548 Q35630635-819A03E0-C6AC-41CC-8B7B-4D02C3675CE8 Q35682519-C4FD8E74-8D9A-42C4-8058-62B25D180C44 Q35758954-D196C0A3-CC0F-4FFF-BCD7-B83EEB01FEF6 Q36150549-93FE82A3-CD58-4772-BF68-5A5C53262971 Q36206108-B1DFED1D-481D-4A0E-8735-3AF39DF2B391 Q36349456-62EDFBFB-2E55-4DDC-B4A0-DF3D832A2968 Q36464062-64EEAA19-4F22-4EAB-9CBB-1A0A4153E102 Q36746411-5627606D-446E-4CD3-AC48-0C462B17BA44 Q36903905-C82BCFCE-5CD6-433C-ABE1-6A9F0D7C8F77 Q36942310-36713C03-C7AB-4899-8EDF-4CB2DE8E4F3C Q36988748-505C2C0B-6882-4A5F-97B1-F0B487145383 Q37122279-81CBB669-FD22-4B38-8BB5-381784028608 Q37187535-D3476E98-3507-428A-8DB2-C207E944FC71 Q37228619-76422C31-539B-44C3-9354-D06B9BE1E0F5 Q37263602-E68E087C-F04F-458B-AD40-49F0730FA88C Q37342892-89B8938A-E9B4-4D41-9E95-655C3DAF9785 Q37418140-27CD1663-4477-437E-9D1F-9AE68F4F001F Q37604753-8AB5EDD0-C656-4AD5-99B2-6E91A690B384 Q37686155-00447CC1-FF8E-4966-9350-8EE4C1554D2A Q37713060-F4A6F763-1B62-460F-946D-82C5C1319500 Q38067660-AF44FEB5-CBA9-48CC-B560-BE157A32C85A Q38261508-E09EB3F1-447A-43C2-8756-9C69532EBA2B Q38308481-C1F2A7E2-C251-422C-8572-5051F1DBAB8A Q38461294-9449F7AE-CFA4-419C-9EE4-6780C66FE97C Q38566131-2D742D29-31E2-4C4F-8D2F-C54C4A1C7EB6 Q38681101-3136C9AE-04C8-4F53-8174-9AB03A64EEFC

P2860

Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care.

http://www.wikidata.org/entity/Q36492436

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Risk factors for chronic kidne ...... viral therapy in routine care.

@ast

Risk factors for chronic kidne ...... viral therapy in routine care.

@en

type

label

Risk factors for chronic kidne ...... viral therapy in routine care.

@ast

Risk factors for chronic kidne ...... viral therapy in routine care.

@en

prefLabel

Risk factors for chronic kidne ...... viral therapy in routine care.

@ast

Risk factors for chronic kidne ...... viral therapy in routine care.

@en

P1433

Q36492436-B7FFB3E8-4302-4F37-A99F-C323FF338F55

P1476

Q36492436-03A3E35C-672C-45AC-94C7-837F6B9CCC24

P2093

Q36492436-0154AF69-9D55-404D-A0DB-4906873D9717

Q36492436-34C2915A-A00A-496A-A682-E77451575E09

Q36492436-366A4A9D-5CCC-47B2-A06B-D528591EE4EB

Q36492436-4C59D1E3-10C1-4FD4-9BC3-B90E3B2542DC

Q36492436-77045279-7D16-4775-9590-10AE089D9084

Q36492436-8DDDA31E-A8E6-434E-9C88-559519B719A6

Q36492436-A9AFE83C-A0EF-4B47-B361-A3C9D89A921B

Q36492436-C5877C56-BC89-49C8-AD1D-0437DEB6AB46

Q36492436-CBA8EE8D-831B-4268-B83F-A79657FFB439

Q36492436-E17590C7-F9EB-45E4-BDF0-BCE8D321E2E2

P2860

Q36492436-05EFDAD5-E70B-4C3D-AEEE-924E3B729449

Q36492436-08AA3A76-9A55-4B31-815D-6E4A85B3BDE2

Q36492436-0CCA6506-DF6A-4DD9-A3FE-D201447F6CE2

Q36492436-0FFADEC1-5C35-433B-B5A2-125CFBAC752B

Q36492436-202E25A5-E34C-4DBD-B669-9BBB7F3C2CB6

Q36492436-21592F25-4FD2-40BF-945C-16C7143F19EB

Q36492436-22C7390C-581C-4F4E-95A0-05D571E25B9F

Q36492436-29D579C8-6366-4B9E-81E1-41C183A4F7A7

Q36492436-2FDA9341-5A91-4FC0-B24B-6D9551EAFFD6

Q36492436-34EC735C-07BB-42F7-864A-FE354A1896E3

P304

Q36492436-E7B248C4-76DF-4E0D-9C5C-2299910EAE03

P31

Q36492436-AD05F80D-53F5-4488-A3D8-4D306C9B30CE

P356

Q36492436-8E259463-280A-42D9-93DA-7C88DD561CE2

P407

Q36492436-6C4CBDB2-CA37-4E3E-AB50-2732037A1634

P433

Q36492436-2F923EA7-7CE5-4062-BBF8-81A7EA60177D

P478

Q36492436-981F5BFA-2B7A-4495-B1D2-DE253BB14A10

P50

Q36492436-040B6008-397B-45CE-A0BC-D80ED13E4106

Q36492436-C89D96D7-9E9B-4EB3-8594-18E05A12309E

P577

Q36492436-5CC06D53-C7B8-4F87-9168-D9CF11CFEF39

P698

Q36492436-EA4A5D1A-14D7-4F20-8C26-40B7D2B7D9BA

P921

Q36492436-487B327B-949A-4633-8942-099987EE31D2

Q36492436-C9039229-62DF-4E11-90CD-0114B9B57A6A

P932

Q36492436-99743730-430A-4DB8-A9E2-A6AC559E4A49

P356

QAD.0B013E328357F5ED

P1433

P1476

Risk factors for chronic kidne ...... viral therapy in routine care.

@en

P2093

Bryan Lau

http://www.w3.org/2001/XMLSchema#string

Heidi M Crane

http://www.w3.org/2001/XMLSchema#string

James H Willig

http://www.w3.org/2001/XMLSchema#string

Jeffrey N Martin

http://www.w3.org/2001/XMLSchema#string

Mari M Kitahata

http://www.w3.org/2001/XMLSchema#string

Rhoderick N Mechekano

http://www.w3.org/2001/XMLSchema#string

Richard D Moore

http://www.w3.org/2001/XMLSchema#string

Robert A Salata

http://www.w3.org/2001/XMLSchema#string

Robert C Kalayjian

http://www.w3.org/2001/XMLSchema#string

Zipporah Krishnasami

http://www.w3.org/2001/XMLSchema#string

P2860

A new equation to estimate glomerular filtration rate

The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis

Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Improving propensity score weighting using machine learning.

Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.

HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy

Proteinuria, creatinine clearance, and immune activation in antiretroviral-naive HIV-infected subjects.

Kidney function and the risk of cardiovascular events in HIV-1-infected patients

P304

1907-1915

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAD.0B013E328357F5ED

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Benigno Rodriguez

P577

2012-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22824630

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

3531628

http://www.w3.org/2001/XMLSchema#string